These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8986821)

  • 21. Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma.
    Gottlieb DJ; Li YC; Lionello I; Tanzarella S; Marangolo M; Bradstock KF; Russo V; Traversari C
    Br J Cancer; 2006 Jul; 95(2):181-8. PubMed ID: 16819544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action.
    Mitchell MS; Harel W; Kan-Mitchell J; LeMay LG; Goedegebuure P; Huang XQ; Hofman F; Groshen S
    Ann N Y Acad Sci; 1993 Aug; 690():153-66. PubMed ID: 8368734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.
    Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Dudley ME; Somerville R; Wunderlich JR; Sherry RM; Yang JC; Rosenberg SA; Kammula US
    Clin Cancer Res; 2015 Feb; 21(3):534-43. PubMed ID: 25424856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Broadening the repertoire of melanoma-associated T-cell epitopes.
    Frøsig TM; Lyngaa R; Met Ö; Larsen SK; Donia M; Svane IM; Thor Straten P; Hadrup SR
    Cancer Immunol Immunother; 2015 May; 64(5):609-20. PubMed ID: 25854582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphocyte-melanoma interaction: role of surface molecules.
    Becker JC; Bröcker EB
    Recent Results Cancer Res; 1995; 139():205-14. PubMed ID: 7597291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
    Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
    Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy.
    Kan-Mitchell J; Huang XQ; Steinman L; Oksenberg JR; Harel W; Parker JW; Goedegebuure PS; Darrow TL; Mitchell MS
    Cancer Immunol Immunother; 1993 Jul; 37(1):15-25. PubMed ID: 8513449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation.
    Schwartzentruber DJ; Topalian SL; Mancini M; Rosenberg SA
    J Immunol; 1991 May; 146(10):3674-81. PubMed ID: 1902860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression.
    Murray JL; Hudson JM; Ross MI; Zhang HZ; Ioannides CG
    J Immunother; 2000 Jan; 23(1):28-35. PubMed ID: 10687135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.
    Schendel DJ; Gansbacher B; Oberneder R; Kriegmair M; Hofstetter A; Riethmüller G; Segurado OG
    J Immunol; 1993 Oct; 151(8):4209-20. PubMed ID: 8409397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.
    Gervois N; Heuze F; Diez E; Jotereau F
    Eur J Immunol; 1990 Apr; 20(4):825-31. PubMed ID: 1971794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.
    Shamamian P; Mancini M; Kawakami Y; Restifo NP; Rosenberg SA; Topalian SL
    Cancer Immunol Immunother; 1994 Aug; 39(2):73-83. PubMed ID: 7519127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual expression of human leukocyte antigen molecules and the B7-1 costimulatory molecule (CD80) on human melanoma cells after particle-mediated gene transfer.
    Albertini MR; Emler CA; Schell K; Tans KJ; King DM; Sheehy MJ
    Cancer Gene Ther; 1996; 3(3):192-201. PubMed ID: 8725884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma.
    LeMay LG; Kan-Mitchell J; Goedegebuure P; Harel W; Mitchell MS
    Cancer Immunol Immunother; 1993 Aug; 37(3):187-94. PubMed ID: 8101473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.
    Wang RF; Parkhurst MR; Kawakami Y; Robbins PF; Rosenberg SA
    J Exp Med; 1996 Mar; 183(3):1131-40. PubMed ID: 8642255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A CD4+, HLA-DR7-restricted T-helper lymphocyte clone recognizes an antigen shared by human malignant melanoma and glioma.
    Somasundaram R; Swoboda R; Caputo L; Lee A; Jackson N; Marincola FM; Guerry D; Herlyn D
    Int J Cancer; 2003 Apr; 104(3):362-8. PubMed ID: 12569560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.